Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Kinaxo Enters in to an Agreement with AstraZeneca

Published: Wednesday, January 05, 2011
Last Updated: Wednesday, January 05, 2011
Bookmark and Share
Under the terms of the agreement, Kinaxo will apply its quantitative mass spec technology platform to support one of AstraZeneca’s oncology programs.

Kinaxo will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. Since protein modifications play pivotal roles in many cellular processes (e.g. cell death or DNA repair) such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets. Financial details of the agreement were not disclosed.


Dr. Henrik Daub, CTO at Kinaxo commented: “Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action. We are delighted to apply our expertise to support AstraZeneca’s research in such highly promising fields of investigation. This collaboration further strengthens Kinaxo’s position as a preferred technology partner for global pharmaceutical companies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KINAXO Extends Collaboration with Takeda
KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout ® to assist in research of drugs under development at Takeda.
Tuesday, April 05, 2011
Kinaxo Extends its Collaboration with Roche
KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche.
Wednesday, January 13, 2010
KINAXO Expands Technology Platform and Secures Additional Venture Capital
KINAXO is expanding its technology platform include mass spectrometry to serve the increasing demand of the pharmaceutical industry for chemical proteomics analyses.
Tuesday, May 08, 2007
Scientific News
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Coding and Computers Help Spot Methane, Explosives
Coded apertures improve and shrink mass spectrometers for field use.
Why Bearcats Smell Like Buttered Popcorn
Researchers pinpoint chemical compound that gives rare animal its popcorn-like scent.
UCSD Scientists Receive NIH Grant to Combat Antibiotic Resistance
Interdisciplinary program will use systems biology approaches to understand how antibiotics work in concert with patient’s immune system.
Virus Causing Tilapia Die-Offs Identified
Discovery of the virus causing Tilapia die-offs in Israel and Ecuador points the way to protecting a fish that feeds multitudes.
Novel Collagen Fingerprinting Identifies A Neanderthal
Study from the universities of Oxford and Manchester uses ZooMS technique to identify traces of an extinct human.
Hope for Combating Muscular Dystrophy
Decoding a sugar molecule and identifying a mechanism linking it to MS could help in the development of therapy for the disease.
Decoding Sugar Molecules Offers New Key For Combating Muscular Dystrophy
Japanese scientists find a rare sugar unit called ribitol 5-phosphate within the sugar molecules on the surface of muscle cells. Mutations in 3 genes linked to muscular dystrophy affect the creation of this sugar molecule.
A Vision for Precision Medicine
The University of Manchester and the University of Dundee partner to share disease screening data.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!